High-Density Lipoproteins and the Kidney.

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Dyslipidemia, characterized by low high-density lipoprotein cholesterol (HDL-c), is prevalent in chronic kidney disease (CKD).
• Reduced HDL-c levels correlate with renal disease progression in mild-to-moderate CKD.
• HDL in CKD patients exhibits altered composition and structure, impairing its protective functions.

Purpose of the Study:

• To review the key alterations in HDL associated with CKD.
• To highlight the role of lecithin-cholesterol acyltransferase (LCAT) in HDL dysfunction and CKD progression.
• To discuss both acquired and genetic LCAT defects in relation to renal disease.

Main Methods:

• Literature review focusing on HDL alterations in CKD.
• Analysis of studies on genetic defects affecting HDL, particularly LCAT deficiency.
• Examination of the link between LCAT levels and CKD progression.

Main Results:

• Low HDL-c is a significant lipid alteration linked to CKD progression.
• Genetic defects in HDL components (apoA-I, apoE, apoL, LCAT) can cause kidney disease.
• LCAT deficiency, both genetic and acquired, mirrors lipid abnormalities in CKD patients.
• Circulating LCAT levels can predict CKD progression.

Conclusions:

• HDL dysfunction is integral to CKD progression.
• LCAT plays a critical role in maintaining HDL function and renal health.
• Understanding LCAT's role offers insights into managing CKD progression.